COVID-19
Conditions
Keywords
SARS-CoV-2, effectiveness, hybrid immunity, booster immunization, adaptive platform trial
Brief summary
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the majority of whom with hybrid immunity of COVID-19 vaccination and COVID-19 breakthrough infection. Individuals aged 18 years and over, include the elderly over 60 years old or those with underlying diseases (history of underlying medical conditions diagnosed by a clinician, including hypertension, diabetes, heart disease, etc). The eligible participants with an interval ≥ 4 months after previous SARS-CoV-2 infection (or had never been infected) and ≥ 6 months from the first COVID-19 vaccine booster will be recruited. Participants who are not willing to receive the second booster but are consent to participate the surveillance for COVID-19, will be included as a blank control. Informed consent will be acquired from eligible participants. Other participants who are willing to receive the second booster and participate the surveillance for COVID-19, will be randomly allocated in a ratio of 1: k (k is the number of vaccine types) to the different investigational vaccines, stratified according to age and history of COVID-19 infection. The symptomatic COVID-19 cases will be reported and documented in both the investigational and control groups. The occurrence of serious adverse events within 6 months after vaccination will be observed. Moreover, blood and nasal mucosa samples will be collected on the day 0 before and day 14, month 3 and 6 after the booster vaccination in a subgroup for humoral, cellular and mucosal immunogenicity analysis. Moreover, oral specimens will be collected once for all participants on the day of enrollment.
Interventions
BIOLOGICALIntramuscularly administered Ad5-nCoV vaccine
This vaccine is produced by CanSino Biologics Inc.
BIOLOGICALAerosolized Ad5-nCoV
This vaccine is produced by CanSino Biologics Inc.
BIOLOGICALDelNS1-2019-nCoV-RBD-OPT1
This vaccine is produced by Wantai Biopharmaceutical Company.
BIOLOGICALSYS6006
This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
Sponsors
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Adults aged 18 years and over, including the elderly over 60 years and those with underlying diseases. 2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol and sign the informed consent form. 3. ≥ 4 months from the last SARS-CoV-2 infection (or never been infected), and 6 months or more from the first booster immunization of the COVID-19 vaccine.
Exclusion criteria
1. Volunteers have suspected symptoms of COVID-19 when enrolled, such as dry throat, sore throat, cough, etc. 2. The COVID-19 Antigen Quick Test Kit is positive when volunteers are enrolled. 3. Fever, temperature \> 37.0°C. 4. Have received a second COVID-19 vaccine booster immunization. 5. Have a history of serious adverse reactions related to the vaccine and/or have a history of severe allergic reactions to any component of the investigational vaccine (only applicable to the vaccine groups). 6. Pregnant or lactating women. 7. HIV infection, tuberculosis, low immunity caused by disease or long-term medication. 8. Acute disease or acute onset of chronic disease. 9. Epilepsy and other progressive neurological disorders. 10. Other situations that are not suitable for participating in this research, according to the judgment of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of COVID-19 from 14 days to 6 months after the booster immunization. | from 14 days to 6 months after the booster dose |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of hospitalized COVID-19 from 7 days to 6 months after the booster immunization. | from 7 days to 6 months the booster dose |
| GMT, GMFI and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on month 6 after the booster vaccination in the immunogenic subgroup. | On month 6 after the booster vaccination |
| GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on day 14 after the booster vaccination in the immunogenic subgroup. | On day 14 after the booster vaccination |
| GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on month 3 after the booster vaccination in the immunogenic subgroup. | On month 3 after the booster vaccination |
| GMT, GMFI and seroconversion of S-RBD-specific IgG antibodies against wild-type SARS-CoV-2 and omicron variant on month 6 after the booster vaccination in the immunogenic subgroup. | On month 6 after the booster vaccination |
| GMT, GMFI and seroconversion of nasal specific IgA antibodies on day 14 after the booster vaccination in the immunogenic subgroup. | On day 14 after the booster vaccination |
| GMT, GMFI and seroconversion of nasal specific IgA antibodies on month 3 after the booster vaccination in the immunogenic subgroup. | On month 3 after the booster vaccination |
| GMT, GMFI and seroconversion of nasal specific IgA antibodies on month 6 after the booster vaccination in the immunogenic subgroup. | On month 6 after the booster vaccination |
| The incidence of serious adverse events within 6 months after the booster vaccination. | within 6 months after the booster dose |
| The incidence of COVID-19 from 7 days to 6 months after the booster immunization. | from 7 days to 6 months the booster dose |
| The incidence of COVID-19 from 28 days to 6 months after the booster immunization. | from 28 days to 6 months the booster dose |
| The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 7 days to 6 months after the booster immunization. | from 7 days to 6 months the booster dose |
| The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 14 days to 6 months after the booster immunization. | from 14 days to 6 months the booster dose |
| The incidence of graded COVID-19 (mild, moderate, severe, critical or death) from 28 days to 6 months after the booster immunization. | from 28 days to 6 months the booster dose |
| The incidence of hospitalized COVID-19 from 14 days to 6 months after the booster immunization. | from 14 days to 6 months the booster dose |
| The incidence of hospitalized COVID-19 from 28 days to 6 months after the booster immunization. | from 28 days to 6 months the booster dose |
| Geometric mean titer (GMT), Geometric mean fold increase (GMFI) and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on day 14 after the booster vaccination in the immunogenic subgroup. | On day 14 after the booster vaccination |
| GMT, GMFI and seroconversion of neutralizing antibodies against wild-type SARS-CoV-2 and omicron variant on month 3 after the booster vaccination in the immunogenic subgroup. | On month 3 after the booster vaccination |
Other
| Measure | Time frame |
|---|---|
| The effectiveness for preventing COVID-19 on day 28 after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. | on day 28 after the booster dose |
| Cross-neutralizing antibody levels against other variants on day 14 after the booster vaccination in the immunogenic subgroup. | On day 14 after the booster vaccination |
| Cross-neutralizing antibody levels against other variants on month 3 after the booster vaccination in the immunogenic subgroup. | On month 3 after the booster vaccination |
| Cross-neutralizing antibody levels against other variants on month 6 after the booster vaccination in the immunogenic subgroup. | On month 6 after the booster vaccination |
| Effectiveness and immunogenicity after the second booster immunization will be subgroup analyzed in the elderly over 60 years old and those with underlying diseases. | from 14 days to 6 months after the booster dose |
| The impact of the human genome on the effect of vaccination. | from 14 days to 6 months after the booster dose |
| The effectiveness for preventing COVID-19 from 14 days after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. | on day 14 after the booster dose |
| The effectiveness for preventing COVID-19 from 7 days after the booster dose will be analyzed stratified based on the S-RBD IgG antibody level at enrollment. | on day 7 after the booster dose |
Countries
China
Contacts
Primary ContactJing-Xin Li, PhD
Outcome results
None listed